Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder

NCT05712187 is registered in ClinicalTrials.gov with Alto Neuroscience as lead sponsor.

NCT NCT05712187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05712187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder
Lead sponsor
Alto Neuroscience
Phase
Phase 2
Overall status
Completed
Start date
January 10, 2023
Completion date
October 24, 2024
Enrollment
301 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder